RPG Investment Advisory LLC trimmed its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 1.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,299 shares of the exchange traded fund’s stock after selling 414 shares during the quarter. RPG Investment Advisory LLC’s holdings in SPDR S&P Biotech ETF were worth $2,598,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. First Heartland Consultants Inc. increased its holdings in SPDR S&P Biotech ETF by 41.8% in the 3rd quarter. First Heartland Consultants Inc. now owns 7,129 shares of the exchange traded fund’s stock valued at $704,000 after buying an additional 2,100 shares during the period. Nations Financial Group Inc. IA ADV increased its holdings in SPDR S&P Biotech ETF by 1.2% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 30,363 shares of the exchange traded fund’s stock valued at $3,000,000 after buying an additional 372 shares during the period. Venturi Wealth Management LLC increased its holdings in SPDR S&P Biotech ETF by 11,345.5% in the 3rd quarter. Venturi Wealth Management LLC now owns 1,259 shares of the exchange traded fund’s stock valued at $124,000 after buying an additional 1,248 shares during the period. Jaffetilchin Investment Partners LLC increased its holdings in SPDR S&P Biotech ETF by 3.9% in the 3rd quarter. Jaffetilchin Investment Partners LLC now owns 4,450 shares of the exchange traded fund’s stock valued at $440,000 after buying an additional 166 shares during the period. Finally, United Capital Management of KS Inc. increased its holdings in SPDR S&P Biotech ETF by 24.0% in the 3rd quarter. United Capital Management of KS Inc. now owns 170,527 shares of the exchange traded fund’s stock valued at $16,848,000 after buying an additional 33,044 shares during the period.
SPDR S&P Biotech ETF Trading Down 2.9 %
Shares of SPDR S&P Biotech ETF stock opened at $100.51 on Wednesday. The firm has a market capitalization of $7.66 billion, a PE ratio of 11.47 and a beta of 1.11. The firm’s 50 day moving average is $99.04 and its 200 day moving average is $95.95. SPDR S&P Biotech ETF has a 1 year low of $64.99 and a 1 year high of $105.47.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Is Bitcoin’s Trump Card a Boom or Bust?
- Using the MarketBeat Stock Split Calculator
- Cloudflare Is a Solid Buy for 2025
- Best Stocks Under $10.00
- Top 3 Hotel Stocks to Watch: A Buy, Hold, and Trade Opportunity
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.